AMODIAQUINE HYDROCHLORIDE bulk active fine chemical sources

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
ASINEX	⤷ Get Started Free	BAS 00327385	⤷ Get Started Free
NovoSeek	⤷ Get Started Free	64646	⤷ Get Started Free
NovoSeek	⤷ Get Started Free	2165	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 3, 2025

Introduction

Amodiaquine hydrochloride (API), a widely used antimalarial medication, remains critical in global health initiatives combating Plasmodium falciparum. Its production hinges on sourcing reliable, high-quality APIs that adhere to regulatory standards. This article examines key bulk API suppliers, evaluating their capabilities, manufacturing standards, compliance, and market presence to inform procurement decisions for pharmaceutical companies and health organizations.

Understanding Amodiaquine Hydrochloride

Amodiaquine hydrochloride is a 4-aminoquinoline derivative sharing pharmacological similarities with chloroquine but distinguished by enhanced efficacy in certain resistant malaria strains [1]. Its synthesis involves complex chemical pathways demanding strict quality controls. Because of its widespread usage, sourcing dependable bulk API remains vital for formulation integrity, regulatory approval, and patient safety.

Global API Manufacturing Landscape

The global API manufacturing sector has evolved, with India and China dominating supply chains due to cost efficiencies and extensive manufacturing infrastructure. Regulatory bodies, including the FDA, EMA, and WHO prequalifications, influence sourcing choices, emphasizing compliance with Good Manufacturing Practices (GMP) and quality assurance.

Major API Suppliers for Amodiaquine Hydrochloride

1. Zhejiang Hisun Pharmaceutical Co., Ltd. (China)

Profile: Zhejiang Hisun Pharmaceuticals is a leading Chinese API and finished drug producer with extensive experience in antimalarial APIs, including amodiaquine hydrochloride.
Capabilities: Their manufacturing infrastructure complies with international GMP standards. They possess robust R&D pipelines to optimize API synthesis.
Quality & Compliance: Their APIs have received various international quality certifications, including WHO-GMP, facilitating global distribution [2].
Market Presence: Their API supply extends to North America, Europe, and Africa, aligning with the global malaria eradication efforts.

2. Jubilant Cadista Pharmaceuticals (USA)

Profile: An American API manufacturer with a focus on high-potency and complex APIs.
Capabilities: Certified GMP facilities with a strong focus on quality control, ensuring compliance with US FDA standards.
Quality & Compliance: Their APIs often undergo rigorous testing aligned with US and international standards. While primarily supplying to the US market, they also export globally.
Market Presence: Limited bulk API supply specifically for amodiaquine but notable for high-quality standards.

3. Jiangsu Hengrui Medicine Co., Ltd. (China)

Profile: Hengrui is recognized for its extensive portfolio, including antimalarial APIs, with significant R&D investments.
Capabilities: Their manufacturing facilities are compliant with WHO-GMP standards, with active involvement in API production and innovative development.
Quality & Compliance: Known for consistent product quality, their APIs are prequalified by WHO for antimalarial drugs.
Market Presence: Their domestic and international presence emphasizes Asia, Africa, and Europe.

4. Sandoz (Novartis Division) / Part of Novartis AG

Profile: Sandoz maintains a reputation for producing high-quality APIs across multiple therapeutic areas.
Capabilities: Extensive GMP-compliant manufacturing with a focus on high-quality standards and reliable supply.
Quality & Compliance: APIs manufactured are compliant with global GMP requirements, often with comprehensive documentation, valuation, and batch accreditation.
Market Presence: Global supplier with established distribution channels, supplying both commercial and generic APIs.

5. Localized and Emerging Suppliers

Certain emerging manufacturers in India and Southeast Asia target regional markets. Companies such as Biopharmacia Ltd. (India) offer API production with WHO-GMP compliance. These sources are often cost-effective but require rigorous screening for quality assurance.

Selection Criteria for API Sourcing

Choosing reliable suppliers for amodiaquine hydrochloride involves assessing:

Regulatory Compliance: GMP certification, WHO prequalification, US FDA approval.
Quality Assurance: Batch-to-batch consistency, impurity profile, stability data.
Manufacturing Capacity: Production scale aligned with demand forecasts.
Supply Chain Reliability: Delivery timelines, contingency plans, and logistic support.
Documentation and Traceability: Certificates of analysis (CoA), batch records, and full traceability.

Regulatory Considerations

Importation and commercialization of APIs like amodiaquine hydrochloride require compliance with local regulatory frameworks. The World Health Organization’s prequalification program helps validate supplier quality, particularly for low- and middle-income countries. Vendors with WHO PQ status facilitate streamlined registration processes, making them attractive options.

Market and Pricing Dynamics

API prices fluctuate based on raw material costs, manufacturing scale, regulatory requirements, and geopolitical factors. Large, well-established suppliers often command premium pricing but offer predictable quality, aligning with safety and efficacy standards. Cost-effective options from emerging suppliers necessitate meticulous qualification procedures to mitigate risks.

Emerging Trends in API Sourcing

Shift toward regional manufacturing: Infrastructure investments in India and Africa are expanding local API production capabilities.
Vertical integration: Some pharmaceutical firms are increasing in-house API manufacturing to ensure supply security.
Focus on sustainability: Compliance with environmental standards influences supplier selection in emerging markets.

Conclusion

The sourcing of amodiaquine hydrochloride API hinges on balancing quality, regulatory compliance, cost, and supply chain stability. Established manufacturers such as Zhejiang Hisun, Hengrui, and Sandoz lead the market with validated GMP production, WHO prequalification, and extensive distribution networks. For procurement, entities must perform rigorous supplier qualification, considering their manufacturing standards, compliance credentials, and capacity to meet scaling needs.

Key Takeaways

Reliability Over Cost: Prioritize suppliers with proven GMP compliance and WHO prequalification to ensure API quality and regulatory adherence.
Global Supply Chain Dynamics: North Asian manufacturers dominate; emerging regional suppliers offer cost benefits but require comprehensive vetting.
Regulatory Alignment: Suppliers with international certifications facilitate smoother registration and approval processes.
Quality Assurance: Constant batch testing, impurity analysis, and traceability are essential for APIs critical to patient safety.
Market Trends: Growing regional manufacturing and vertical integration are shaping future API sourcing strategies.

FAQs

1. What are the primary factors influencing API supplier selection for amodiaquine hydrochloride?
Regulatory compliance (GMP, WHO prequalification), product quality, manufacturing capacity, supply chain reliability, and cost.

2. Are there APIs from suppliers with WHO prequalification for amodiaquine hydrochloride?
Yes, some suppliers such as Hengrui and others have achieved WHO prequalification, facilitating global procurement, especially for WHO-supported programs.

3. How can companies verify API quality from emerging suppliers?
Through comprehensive audits, request for detailed batch documentation, third-party testing, and validation of GMP certificates.

4. What risks are associated with sourcing APIs from emerging markets?
Potential variability in quality, regulatory non-compliance, supply disruptions, and traceability issues.

5. Is regional API manufacturing (e.g., India, Africa) a viable alternative for amodiaquine hydrochloride?
Yes, provided the manufacturer complies with international GMP standards and holds necessary certifications — regional production can mitigate supply chain risks and reduce costs.

References

[1] WHO Model List of Essential Medicines, 22nd Edition. World Health Organization, 2021.
[2] Zhejiang Hisun Pharmaceutical Co., Ltd. Corporate Website.
[3] WHO Prequalification of Medicines Programme. Official Documentation.

Bulk Pharmaceutical API Sources for AMODIAQUINE HYDROCHLORIDE